Normal view MARC view ISBD view

Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future. [Review]

MedStar author(s):

Citation: Clinics in Liver Disease. 24(4):739-753, 2020 11.PMID: 33012456Institution: MedStar Washington Hospital CenterDepartment: Hematology and OncologyForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Carcinoma, Hepatocellular/dt [Drug Therapy] | *Immune Checkpoint Inhibitors/tu [Therapeutic Use] | *Liver Neoplasms/dt [Drug Therapy] | Antineoplastic Agents, Immunological/tu [Therapeutic Use] | Carcinoma, Hepatocellular/im [Immunology] | Humans | Liver Neoplasms/im [Immunology] | Protein Kinase Inhibitors/tu [Therapeutic Use]Year: 2020 ISSN:

1089-3261

Name of journal: Clinics in liver diseaseAbstract: Hepatocellular carcinoma is a highly prevalent and lethal cancer that many therapeutics are being tested for this disease. It has the potential to be a highly immune-responsive tumor given its inflammatory origins. The first immunotherapies were anti-programmed death-1 monotherapies, which improved response rates and survival. Novel immunotherapy combinations and immunotherapy show promise in frontline treatment. The novel antibody therapy combination of atezolizumab and bevacizumab may be practice changing. Although these landmark studies seem to offer new treatment options, the role of immunotherapy in the liver transplant setting is uncertain until the safety of this approach is defined. Copyright (c) 2020 Elsevier Inc. All rights reserved.All authors: Armstrong SA, He AROriginally published: Clinics in Liver Disease. 24(4):739-753, 2020 Nov.Fiscal year: FY2021Digital Object Identifier:

https://dx.doi.org/10.1016/j.cld.2020.07.007

Date added to catalog: 2020-12-29

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	33012456	Available		33012456

Hepatocellular carcinoma is a highly prevalent and lethal cancer that many therapeutics are being tested for this disease. It has the potential to be a highly immune-responsive tumor given its inflammatory origins. The first immunotherapies were anti-programmed death-1 monotherapies, which improved response rates and survival. Novel immunotherapy combinations and immunotherapy show promise in frontline treatment. The novel antibody therapy combination of atezolizumab and bevacizumab may be practice changing. Although these landmark studies seem to offer new treatment options, the role of immunotherapy in the liver transplant setting is uncertain until the safety of this approach is defined. Copyright (c) 2020 Elsevier Inc. All rights reserved.

English